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BACKGROUND. Metastatic prostate cancer is an incurable disease. During the develop-
ment of this disease, prostate cancer cells enter the bloodstream as single cells or clusters of
cells. Prostate fibroblasts, a cancer-promoting cell type in the prostate cancer microenviron-
ment, could in theory incorporate into these migrating cell clusters or follow cancer cells into
the bloodstream through holes in the tumor vasculature. Based on this idea, we hypothesized
that fibroblast-like cells, defined here as cytokeratin 8/18/19/DAPIþ/CD45/vimentinþ
cells, are present in the blood of men with metastatic prostate cancer.
METHODS. Veridex’s CellSearch1 system was used to immunomagnetically capture
EpCAMþ cells and clusters of cells heterogeneous for EpCAM expression from the blood of
men with metastatic prostate cancer, localized cancer, and no known cancer, and immuno-
stain them for the presence of cytokeratins 8/18/19, a nucleus, CD45, and vimentin.
Fibroblast-like cells were then quantified.
RESULTS. Fibroblast-like cells were present in 58.3% of men with metastatic prostate cancer
but not in any men with localized prostate cancer or no known cancer. The presence of
these cells correlated with certain known indicators of poor prognosis: 5 circulating tumor
cells, defined here as cytokeratin 8/18/19þ/DAPIþ/CD45 cells, per 7.5 ml of blood, and a
relatively high serum prostate-specific antigen level of 20 ng/ml.
CONCLUSIONS. The presence of fibroblast-like cells in the blood may provide
prognostic information as well as information about the biology of metastatic prostate cancer.
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INTRODUCTION
Metastatic prostate cancer poses a significant risk
to men, with 67% of men dying within 5 years of diag-
nosis [1]. This disease is often treated initially with
hormone therapies but almost always eventually
becomes resistant [2]. In order to develop novel strate-
gies for preventing and/or treating metastatic pros-
tate cancer, we need to better understand the biology
of metastasis, including the biology of the blood dur-
ing metastasis.
Before cancer cells capable of metastasis enter sec-
ondary sites, they must first invade through the base-
ment membrane at the primary tumor site and enter
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the bloodstream as single cells or in cell clusters [3].
Migrating clusters of cancer cells could, in theory,
incorporate non-cancer cell types such as prostate
fibroblasts, a cell type in the prostate cancer microen-
vironment that induces prostate cancer growth [4–7]
and invasion [8]. Lending credence to this theory is
the fact that metastatic prostate cancer cells express
high levels of N-cadherin [9], a protein that mediates
their adhesion to prostate fibroblasts [10].
It is also possible that prostate fibroblasts enter the
bloodstream as single cells. Tumor vasculature is
leaky [11], suggesting that cells from a tumor micro-
environment could enter the bloodstream through
holes in vessel walls. Furthermore, prostate fibro-
blasts invade through collagen I in response to pros-
tate cancer-derived angiogenin [12,13], suggesting
that they may follow migrating prostate cancer cells
into the bloodstream.
Based on these concepts, we hypothesized that
fibroblast-like cells are present in the blood of men
with metastatic prostate cancer but not in the blood
of men with localized prostate cancer or no known
cancer. To test this hypothesis, we used Veridex’s
CellSearch1 system to capture circulating CK/
DAPIþ/CD45/vimþ, or fibroblast-like, cells, which
were then quantified. The presence of fibroblast-like
cells in the blood may provide both prognostic infor-
mation and information about the biology of meta-
static prostate cancer.
MATERIALSANDMETHODS
StudyParticipants
Participants with localized prostate cancer and
those with metastatic, castration-resistant prostate
cancer were identified in a medical oncology clinic,
while cancer-free participants were recruited through
advertising for normal controls. All participants con-
sented to participate in this study per IRB-approved
protocol. Their characteristics are delineated in
Table I.
BloodSampleCollection
Blood samples (10 ml/sample) from 14 men with
metastatic prostate cancer (2 for an initial experiment,
presented in Fig. 1B,C), 10 with localized prostate can-
cer, and 9 without cancer were collected in CellSave
Preservative tubes. During the participant visits when
these blood samples were collected, blood samples
were also collected for serum PSA measurements.
TABLE I. Medicalinformationofstudyparticipants
Cancer status Participant Age PSA level (ng/ml) Gleason score Treatment
Localized PCa 10 64 7.9 3 þ 3 ¼ 6 None
11 70 7.1 3 þ 4 ¼ 7 None
12 64 10.3 4 þ 3 ¼ 7 None
13 63 6.4 3 þ 3 ¼ 6 None
14 70 8.4 4 þ 3 ¼ 7 None
15 67 5.9 3 þ 4 ¼ 7 None
16 53 14.0 3 þ 4 ¼ 7 None
17 68 5.6 3 þ 4 ¼ 7 None
18 54 4.1 3 þ 4 ¼ 7 None
19 60 2.2 3 þ 3 ¼ 6 None
Metastatic PCa 20 46 4.7 4 þ 4 ¼ 8 H
21 86 160.3 7 RRP C H
22 72 12.6 4 þ 4 ¼ 8 RRP RT H
23 69 75.3 4 þ 3 ¼ 7 RT C H
24 57 16.4 9 RRP H
25 82 176.2 3 þ 3 ¼ 6 RT C H
26 65 124.2 3 þ 4 ¼ 7 C H
27 54 4.9 4 þ 5 ¼ 9 H
28 66 95.3 4 þ 3 ¼ 7 RRP RT C H
29 80 68.5 5 þ 4 ¼ 9 RRP C H
30 62 7.7 7 RRP H
31 76 582.0 7 RT C H
Participants 1–9 had no known cancer, and their ages ranged from 22 to 60.
RRP, radical retropubic prostatectomy; RT, radiation therapy at the primary tumor site; C, chemotherapy; H, hormone therapy.
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All blood samples were collected under IRB-
approved protocols at the Johns Hopkins University
School of Medicine (JHSOM) and the University of
Michigan Medical School. The CellSave tubes were
gently inverted five times and then stored at room
temperature for up to 72 hr prior to blood sample
processing as described in Veridex’s CXC kit
protocol.
Fig. 1. CellSearch1 systemprotocol and resultant images and cell counts.A: Diagram depicting the CellSearch1 systemprotocol.Blood
was collected frommen with no known cancer, localized prostate cancer, and metastatic prostate cancer, and loaded onto a CellTracks1
AutoPrep1 system.This system captured EpCAMþ cells, and clusters of cells heterogeneous for EpCAM expression, and stained them for
the epithelial markers cytokeratins 8/18/19 (CK); the presence of a nucleus (DAPI); the lymphocyte marker CD45; and the mesenchymal
marker vimentin (vim).The captured, stained cells were transferred to a CellTracks1 Analyzer II and scanned into CellSearch1 software,
which presented the user with images of cells that could then be quantified. All of the images in a single row depict the same cell or cell
cluster. B,C: Subsets of images of captured, stained cells from one study participant (B) and a second study participant (C) who had
metastatic prostate cancer.D:The number of CKþ/DAPIþ/CD45 cells (i.e., circulating tumor cells, or CTCs) and CK-/DAPIþ/CD45/vimþ
cells (i.e., circulating fibroblast-like cells)per7.5 mlofbloodin9menwithnoknowncancer,10withlocalizedprostate cancer (PCa), and12with
metastatic PCa.E:Thepercentage of studyparticipants in each category (e.g., noknowncancer, localizedPCa, andmetastatic PCa)whohad
CTCs or circulating fibroblast-like cells. , P < 0.001; NS, P > 0.05, compared to CKþ/DAPIþ/CD45 cells in participantswithmetastatic
PCa.,P < 0.01, comparedtoCK/DAPIþ/CD45/vimþcellsinparticipantswithmetastaticPCa.
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Immunomagnetic IsolationofCells
Immediately after processing, the blood samples
(7.5 ml/sample) were loaded onto a CellTracks1
AutoPrep1 System (Fig. 1A), where they were immu-
nomagnetically enriched for EpCAMþ cells and clus-
ters of cells heterogeneous for EpCAM expression.
The system stained the enriched cells with the CXC
kit reagents DAPI, FITC-labeled anti-CK-8/18/19 an-
tibody, and APC-labeled anti-CD45 antibody, as well
as the user-defined reagent PE-labeled anti-vimentin
antibody (Abcam, diluted to 4 or 2 mg/ml in 0.1% bo-
vine serum albumin/PBS for Fig. 1B,C, respectively,
and 3 mg/ml in 0.1% bovine serum albumin/PBS for
Figs. 1D,E and 2). A cartridge containing the enriched,
stained cells was removed from the system and placed
in the dark for 20 min to 24 hr prior to analysis.
AnalysisofCaptured Images
The cartridge containing the enriched, stained cells
was placed in the CellTracks1 Analyzer II, where
the cells were scanned (0.5 sec for the PE channel).
Images of single cells and small cell clusters were
then loaded into the CellSearch1 software and
reviewed by multiple individuals, who enumerated
CK/DAPIþ/CD45/vimentinþ/cells (i.e., circulating
fibroblast-like cells) and CKþ/DAPIþ/CD45 cells
(i.e., circulating tumor cells).
Statistics
For the data presented in Figures 1E and 2A–C,
Fisher’s exact test was performed using a Microsoft
Research online calculator, which generated two-
sided P values.
RESULTS
The overall goal of this study was to determine
whether circulating CK/DAPIþ/CD45/vimentinþ,
or fibroblast-like, cells are present in men with meta-
static prostate cancer. In a preliminary study (out-
lined in Fig. 1A), we found that these cells were
indeed present in both men that we tested; images of
fibroblast-like cells from these men are shown in
Figure 1B,C. These results led us to question whether
the presence of circulating fibroblast-like cells is a
specific feature of metastatic prostate cancer or is gen-
eralizable to all prostate cancers or even all men.
Thus, we performed a larger study in which we eval-
uated their presence in 12 men with metastatic pros-
tate cancer, 10 with localized prostate cancer, and 9
with no known cancer (Table I contains relevant med-
ical information of these participants). Circulating fi-
broblast-like cells were detected in 7 of 12 men with
metastatic prostate cancer and in none of the men
with localized prostate cancer or no known cancer
(Fig. 1D,E).
In men who had detectable levels of circulating
fibroblast-like cells, the cell number ranged from 2 to
12 per 7.5 ml of blood (Fig. 1D). The presence of these
cells correlated with certain known indicators of
poor prognosis: 5 circulating tumor cells (CTCs, or
CKþ/DAPIþ/CD45 cells) per 7.5 ml of blood, and a
relatively high serum prostate-specific antigen (PSA)
level of 20 ng/ml (Fig. 2).
Fig. 2. Correlation of the presence of circulating fibroblast-like cells with known indicators of unfavorable prostate cancer prognosis:
5 CTCs per 7.5 ml of blood (A), a PSA level of 20 ng/ml (B), and both 5 CTCs per 7.5 ml of blood and a PSA level of 20 ng/ml (C).
,P < 0.01;,P < 0.05, comparedtono circulating fibroblast-like cells.
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DISCUSSION
We found that circulating CK/DAPIþ/CD45/
vimentinþ, or fibroblast-like, cells were indeed pres-
ent in study participants with metastatic prostate can-
cer but not in those with localized prostate cancer or
no known cancer. While others have found circulating
cells expressing mesenchymal markers in men with
prostate cancer [14], those cells also expressed epithe-
lial markers such as cytokeratins. In contrast, we
detected circulating cells that express the mesenchy-
mal marker vimentin but not cytokeratins. To our
knowledge, we are the first to detect such cells in
prostate cancer patients. This finding may have both
clinical and biological importance.
From a clinical standpoint, the presence of circulat-
ing fibroblast-like cells in men with prostate cancer
may indicate a poor prognosis. These cells were
detected only in men with metastatic prostate cancer,
an incurable disease. Furthermore, the presence of
these cells correlated with certain known indicators
of poor prognosis: 5 circulating tumor cells (CTCs,
or CKþ/DAPIþ/CD45 cells) per 7.5 ml of blood, and
a relatively high serum prostate-specific antigen
(PSA) level of 20 ng/ml (Fig. 2). These cut-off values
for CTCs and PSA are controversial: depending on
the source, 4 [15] or 5 CTCs [16] per 7.5 ml of
blood, or a post-prostatectomy PSA level of 0.2 ng/
ml [17] or 0.4 ng/ml [18], to name just two, indicates
poor prognosis. Circulating fibroblast-like cells differ
from CTCs and PSA in that it is their presence rather
than any arbitrary cut-off value that seems to correlate
with poor prognosis. Thus, these cells may be more
meaningful than CTCs and PSA as a prognostic
indicator.
From a biological standpoint, our work raises sev-
eral important questions about the pathology of meta-
static prostate cancer. First, did the fibroblast-like
cells that we detected originate from the prostate? If
so, were they prostate fibroblasts, prostate myofibro-
blasts (i.e., cells having characteristics of both smooth
muscle cells and fibroblasts), or prostate cancer cells
that underwent epithelial-to-mesenchymal transition?
We are working on characterizing the fibroblast-like
cells to address these questions.
Another important question raised by our work
is where the circulating fibroblast-like cells go, and
more specifically, whether they go to the bone, a pre-
dominant site for metastatic prostate cancer. The cur-
rent dogma is that the stromal cells, that is, non-
epithelial cells, in the bone of men with metastatic
prostate cancer are bone-derived [19]. Our findings
give rise to the possibility that some of the stromal
cells in their bones are prostate-derived: if the circu-
lating fibroblast-like cells that we found are indeed
prostate fibroblasts, then perhaps prostate fibroblasts
migrate to secondary sites such as the bone and
help cancer grow at those sites. In support of this
hypothesis, Duda et al. [20] found in a mouse model
that carcinoma-associated fibroblasts migrated with
metastasizing cancer cells to the lungs, where they
contributed to the formation of metastatic lesions.
In our study, men with detectable levels of circulat-
ing fibroblast-like cells had cell numbers ranging
from 2 to 12 per 7.5 ml of blood (Fig. 1D). These cell
numbers are low, possibly due to the limited sensitiv-
ity of the CellSearch1 method [21]. Future work
should focus on evaluating the presence of circulating
fibroblast-like cells using a technique that is more sen-
sitive, such as the recently developed Herringbone–
Chip method [22], and more direct (i.e., directly
capture circulating fibroblast-like cells rather than
EpCAMþ cells and cells that have adhered to
EpCAMþ cells). Future studies should also involve
larger numbers of study participants.
CONCLUSIONS
Overall, the results of our study suggest that the
presence of fibroblast-like cells in the blood may dis-
tinguish men who have metastatic prostate cancer
from men who do not. Thus, these cells may have
potential as a prognostic marker and/or therapeutic
target in men with prostate cancer. Further work
needs to be done to evaluate the clinical utility of cir-
culating fibroblast-like cells, including their ability to
predict a poor outcome, and to better understand
their biology, that is, where they came from, where
they end up, and how they contribute to metastatic
progression.
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